NCPA supports drug disposal bills, makes approval recommendations
ALEXANDRIA, Va. A group representing the nation’s independent pharmacies heralded two pieces of legislation that pertain to the safe disposal of prescription drugs.
The National Community Pharmacists Association announced its support of legislative efforts made by the House of Representatives and the Senate, which passed their respective drug disposal bills Wednesday and last month. NCPA also added that it was “a giant step forward to allow for controlled substances, which had previously been precluded from any disposal programs, to be included.”
The lobbying group did, however, express concern that neither bill passed by the legislative bodies will provide liability protections for participating pharmacies nor adequate funding mechanisms or grant programs to assist in the cost of responsible collection. These concerns were conveyed to the House prior to the vote, NCPA said.
“Independent community pharmacists are uniquely positioned to help Americans get rid of expired and unused prescription drugs,” said Joseph Harmison, NCPA president and pharmacy owner. “That’s why over 1,000 member pharmacies are now engaged in a successful drug disposal programs with Sharps Compliance Inc.”
FDA approves multiple sclerosis drug Gilenya
SILVER SPRING, Md. The Food and Drug Administration has approved a drug for reducing relapses in patients with multiple sclerosis.
The FDA announced Wednesday the approval of Swiss drug maker Novartis’ Gilenia (fingolimod) capsules, saying it was the first oral drug that can slow the progression of disability in patients with MS and offered an alternative to injected drugs.
Around 400,000 people in the United States and 2.1 million worldwide have MS, according to the National Multiple Sclerosis Society.
Novartis’ Cushing’s disease drug shows promising results in trial
EAST HANOVER, N.J. Swiss drug maker Novartis said its investigational drug is the first to show promise in a late-stage clinical trial for Cushing’s disease, a potentially fatal hormonal disorder.
Novartis announced Wednesday that the drug SOM230 (pasireotide) had reduced cortisol levels in patients with Cushing’s disease. The disease results from a benign pituitary tumor that causes the adrenal glands to produce excess cortisol. This can lead to metabolic and cardiovascular problems and death. Results will be presented at the 14th congress of the European Neuroendocrine Association.
“There is a critical need for a medical treatment for people with Cushing’s disease because currently available options, such as surgery or radiotherapy, are ultimately not effective for many of the patients who suffer from this debilitating disease,” said William Ludlam, director of the Seattle Pituitary Center at the Swedish Neuroscience Institute in Seattle. “The results of this study suggest that pasireotide may help patients achieve biochemical control of their Cushing’s disease and its symptoms by directly targeting the pituitary tumor that triggers excess cortisol production.”